Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level
暂无分享,去创建一个
H. Park | Sun-Young Lee | I. Sung | J. Kim | Sang Pyo Lee | C. Shim | Sun-Young Lee
[1] M. Joo,et al. Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.
[2] H. Heerkens,et al. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[3] C. Sohn,et al. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia , 2017, Yonsei medical journal.
[4] Hsin-Yao Wang,et al. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers , 2016, PloS one.
[5] Honghe Zhang,et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. , 2015, International journal of clinical and experimental medicine.
[6] O. Lavie,et al. CA 19-9 in Evaluation of adnexal mass: retrospective cohort analysis and review of the literature , 2015, The International journal of biological markers.
[7] P. Maisonneuve,et al. Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis , 2015, Neuroendocrinology.
[8] Se Hyung Kim,et al. Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT , 2014, European Radiology.
[9] Zhenya Song,et al. Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China , 2013, Clinical chemistry and laboratory medicine.
[10] J. Rhee,et al. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[11] A. Mayadağlı,et al. Type 2 diabetes mellitus and CA 19-9 levels. , 2007, World journal of gastroenterology.
[12] A. Siriwardena,et al. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] Z. Yue,et al. Serum tumour markers in patients with chronic kidney disease , 2007, Scandinavian journal of clinical and laboratory investigation.
[14] Daniel F Hayes,et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Magnani. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. , 2004, Archives of biochemistry and biophysics.
[16] J. K. Lee,et al. Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.
[17] Greg L Perkins,et al. Serum tumor markers. , 2003, American family physician.
[18] S. Myung,et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve , 1999, American Journal of Gastroenterology.
[19] T. Homma,et al. CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience , 1994, Pancreas.
[20] K. Migita,et al. Elevation of a tumor associated antigen CA 19-9 levels in patients with rheumatic diseases. , 1989, The Journal of rheumatology.
[21] T. Frebourg,et al. The evaluation of CA 19‐9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients , 1988, Cancer.
[22] Qiwen Ben,et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. , 2011, European journal of cancer.
[23] J. Yim,et al. Increased CA 19-9 level in patients without malignant disease , 2009, Clinical Chemistry and Laboratory Medicine.